ONCOLOGY recently interviewed Dr. Eileen Parkes, whose laboratory studies the STING pathway, to find out why researchers are excited about targeting this pathway as a potential cancer therapy.
Eileen Parkes, MD, PhD
Advertisement
Articles by Eileen Parkes, MD, PhD
Late last year, ONCOLOGY hosted a writing contest on CancerNetwork.com, in which we asked our readers to share their personal experiences with delivering bad news. The essay by Dr. Eileen Parkes from Queen’s University Belfast, United Kingdom, was selected as the first place winner.
Advertisement
Latest Updated Articles
My Signature ScentPublished: March 15th 2018 | Updated:
Eileen Parkes on Why Cancer Researchers Are Excited About STING AgonistsPublished: August 15th 2018 | Updated:
Advertisement
Advertisement
Trending on CancerNetwork
1
More Global Expertise and Talent Are Needed to Administer Cell Therapies
2
FDA Grants Priority Review to Enfortumab Vedotin Combo in MIBC Subset
3
Adaptive Treatment and Other Advances May Drive Radiotherapy Field Forward
4
Simultaneous Integrated Boost Radiotherapy Improves PFS in Cervical Cancer
5
